BioCap 2022 – connecting businesses, research and investors
Our CEO Lorna Green and Innovation Director Dilruk Yahathugoda attended BioNow’s BioCap 2022 event, where Lorna acted as judge for the Digital Pitching Competition and ultimately awarded University of Liverpool’s’ Marie Yang O’Brien’s spin-out company ReNewVax, which aims to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines.
BioNow hosted the event at Alderley Park Conference Centre in Macclesfield, which was attended by a variety of life science businesses, researchers, investors and university delegates. There were three investor insight speakers, Marion Bernard, Chief Investment Officer of Northern Gritstone, Jon Moulton, Chairman and Founder of Better Capital and Dr Avi Spier, Executive Director, Search & Evaluation, NIBR BD&L, Novartis Institutes for BioMedical Research.
The event aimed to connect SMEs and Innovators to businesses, researchers and potential investors, whilst also providing an informative experience to help navigate the life science funding landscape and identify potential investment opportunities that might advance and support their business.
There were a variety of topics discussed at the event, such as the funding landscape in general, challenges that the health and life sciences industry faces, as well as discussing innovators, SME’s and their respective funding issues. Also in discussion was skill shortages within life science and its overall impact on the industry.
Start-ups in attendance also had the opportunity to present their technology and offerings.
BioCap 2022 reassured innovators that post-Covid the focus on investment into SME, innovators and their products is increasing. The support system available for small-scale innovators is increasing, and events like BioCap make investment and collaboration opportunities more accessible within the region.
CEO Lorna Green said “It was a massive honour to present the BioCap 2022 pitching award. The event provided yet another great opportunity for SME’s and innovators to meet with potential investors. As the health and life sciences industry seeks to recover from the pandemic, events like these are massively valuable not just to innovators, but to investors who have a genuine passion for driving innovation within the region”.
LYVA Labs provides the opportunity for SMEs to network with people within innovation and investment, we are actively looking to attend more events of a similar nature.